The standard dose of Adagrasib is 600mg twice daily (2 300mg tablets), taken at 12 hour intervals and continuously administered until disease progression or intolerable toxicity occurs. The long-term safety of its use has been validated in clinical trials, but regular monitoring of adverse reactions is necessary.

1. Conventional usage and dosage

(1) Single dose: Take 600mg orally each time (2 300mg tablets), and swallow the whole tablet.

(2) Medication frequency: Take twice a day at a fixed time, with a strict interval of 12 hours (such as 8am/8pm).

(3) Treatment requirements: Continue taking medication until the disease progresses or the doctor determines that the medication needs to be stopped, with no predetermined treatment period limit.

2. Precautions for administration

(1) Usage: Can be taken with food or on an empty stomach, but should avoid taking with grapefruit products.

(2) Omission treatment: If it is more than 6 hours before the next administration, it can be taken immediately; Skip if ≤ 6 hours and prohibit double dosage.

(3) Dose adjustment: In the event of ≥ grade 3 adverse reactions, administration should be suspended, and may need to be reduced to 400mg per dose after recovery.

3. Long term medication management

(1) Safety data: The median duration of treatment in key trials was 8.2 months, with the longest duration of medication exceeding 2 years.

(2) Monitoring requirements: Regular check of liver function (once every 3 weeks for the first 3 months), electrocardiogram (QT interval), and electrolytes are required.

(3) Discontinuation criteria: Disease progression or irreversible toxicity (such as interstitial lung disease, severe liver injury, etc.).

4. Medication for special populations

(1) Patients with liver injury: Moderate to severe liver dysfunction should reduce the dosage to 300mg/time, twice a day.

(2) Elderly patients: Those aged 65 and above do not need to adjust the dosage, but it is necessary to strengthen the monitoring of adverse reactions.

(3) Drug interactions: Avoid using strong CYP3A4 inhibitors/inducers in combination and adjust the dosage if necessary.